|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300079294 |
|
最近更新日期: Date of Last Refreshed on: |
2023-12-29 11:38:05 |
|
注册时间: Date of Registration: |
2023-12-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
电针治疗老年性肌少症的临床随机对照研究 |
|
Public title: |
Electroacupuncture for Sarcopenia in the Elderly: A Randomized Controlled Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
电针治疗老年性肌少症的临床随机对照研究 |
|
Scientific title: |
Electroacupuncture for Sarcopenia in the Elderly: A Randomized Controlled Trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
鲁凌云 |
研究负责人: |
鲁凌云 |
|
Applicant: |
Lingyun Lu |
Study leader: |
Lingyun Lu |
|
申请注册联系人电话: Applicant telephone: |
+86 185 8395 5132 |
研究负责人电话: Study leader's telephone: |
+86 185 8395 5132 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lingyun.lu@scu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
lingyun.lu@scu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
国学巷37号 |
研究负责人通讯地址: |
国学巷37号 |
|
Applicant address: |
No.37 Guoxue Alley |
Study leader's address: |
No.37 Guoxue Alley |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023年审(525)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-04-26 00:00:00 |
||
|
伦理委员会联系人: |
邓邵林 |
||
|
Contact Name of the ethic committee: |
Shaolin Deng |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
No.37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 85422851 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.37 Guoxue Alley, Wuhou District, Chengdu 610041 |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省科技厅重点研发项目(2023YFS0247) |
||||||||||||||||||||||
|
Source(s) of funding: |
Key Research and Development Project of Science and Technology Department of Sichuan Province (2023YFS0247) |
||||||||||||||||||||||
|
Target disease: |
Sarcopenia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在探讨电针治疗肌少症的临床疗效和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to explore the clinical efficacy and safety of electroacupuncture in treating sarcopenia |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1)符合亚洲肌少症工作组发布的《2019亚洲肌少症诊断共识》中关于“肌少症”的诊断; 2)年龄为60~80岁,性别不限; 3)签署知情同意书,自愿参与本试验。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Meets the diagnostic criteria for "sarcopenia" as outlined in the "2019 Asian Sarcopenia Diagnosis Consensus" published by the Asian Working Group for Sarcopenia; 2) Age between 60 and 80 years old, no gender restrictions; 3) Signs the informed consent form and voluntarily participates in this trial. |
||||||||||||||||||||||
|
排除标准: |
1)曾任职业或半职业运动员; 2)患有可能引起营养不良的基础疾病,包括心力衰竭、慢性阻塞性肺疾病、慢性肾衰竭、厌食症等,可导致老年人食欲减退和消化不良、精神心理障碍和认知功能减退也会导致老年人摄食量下降; 3)患有导致肌肉耗损的基础疾病,如恶性肿瘤、神经肌肉疾病、持续3个月未愈骨折等; 4)身体残疾或上下肢在3个月内受伤或手术可能影响握力或步速测量者; 5)服用对肌肉骨骼功能有重大影响的药物; 6)体内植入电子设备、骨科金属植入物; 7)药物或酒精依赖或滥用者; 8)参与其他临床试验的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Have a background as a professional or semi-professional athlete. 2) Suffer from underlying medical conditions that may lead to malnutrition, such as heart failure, chronic obstructive pulmonary disease (COPD), chronic kidney failure, anorexia, etc. These conditions can result in appetite loss and indigestion among the elderly population. Additionally, mental disorders and cognitive impairment can also contribute to decreased food intake in older individuals. 3) Have underlying diseases that cause muscle wasting, including malignant tumors, neuromuscular disorders, and fractures that have not healed within a three-month period. 4) Experience physical disability or injury to the upper or lower limbs within the past three months which may impact grip strength measurement or walking speed assessment. 5) Take medications known to significantly affect musculoskeletal function. 6) Possess implanted electronic devices or orthopedic metal implants within the body. 7) Struggle with drug or alcohol dependence/abuse issues. 8) Currently enrolled in other clinical trials. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-05-01 00:00:00至 To 2025-12-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-12-29 00:00:00 至 To 2025-12-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参与本试验的统计学家采用电脑随机数字生成器生成随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization will be performed via an online response system operated by a statistician, who has no clinical involvement in this trial. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
统计者、受试者及疗效评价者不知道分组情况 |
|
Blinding: |
The statisticians, patients and evaluators will be unaware of their group allocation |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
课题完成后可联系通讯作者获取原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact the corresponding author to obtain the original data after the completion of the project. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |